SOURCE-LINKED STUDY SUMMARY
Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach.
Abstract summarized · Quality not appraised
- Studied
- A lifetime disease model compared semaglutide plus diet and exercise with diet and exercise alone, estimating health outcomes and carbon emissions.
- Who / model
- The model used STEP and SELECT trial data for UK populations with overweight or obesity, including groups with complications or established cardiovascular disease. No new participant sample is described.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- Found
- Estimated lifetime emissions fell 1.8% and 1.9% in two populations. In established cardiovascular disease, estimated survival rose 0.56 years, but emissions increased from 14,444 to 14,700 kilograms of carbon-dioxide equivalent. These are modelled projections.
- Limits
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Research findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1007/s40273-026-01659-4